Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
190
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Establishment and Verification of UPLC-MS/MS Technique for Pharmacokinetic Drug–Drug Interactions of Selinexor with Posaconazole in Rats

Chen-jian Zhou1 Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, 325027, People’s Republic of China
,
Hui-jun Wang2 School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Chun-yan Zhou2 School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Chao-fan Li2 School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
,
Ming-Jia Zhu2 School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China
&
Xiang-jun Qiu2 School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of ChinaCorrespondence[email protected]
Pages 1561-1568 | Published online: 15 Apr 2021

References

  • Karyopharm Therapeutics Inc. XPOVIO™ (selinexor) tablets, for oral use: US prescribing information; 2019. Available from: www.fda.gov. Accessed 82, 2019.
  • GounderMM, ZerA, TapWD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166–3174. doi:10.1200/JCO.2016.67.6346.27458288
  • Abdul RazakAR, Mau-SoerensenM, GabrailNY, et al. First-in-class, first-in-human Phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–4150. doi:10.1200/JCO.2015.65.3949.26926685
  • GandhiUH, SenapedisW, BalogluE, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(5):335–345. doi:10.1016/j.clml.2018.03.003.29610030
  • TurnerJG, SullivanDM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15:2648–2655. doi:10.2174/09298670878624285918991627
  • GargM, KanojiaD, MayakondaA, et al. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep. 2017;7(1):9749. doi:10.1038/s41598-017-10325-x.28852098
  • RanganathanP, KashyapT, YuX, MengX, GarzonR. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia (AML) by targeting DNA repair and restoring topoisomerase IIα to the nucleus. Clin Cancer Res. 2016;22(24):6142. doi:10.1158/1078-0432.CCR-15-2885.27358488
  • LiuXJ, ChongYL, TuYM, et al. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. J Hematol Oncol. 2016;9:108. doi:10.1186/s13045-016-0338-2.27733172
  • SaulinoDM, YounesPS, BileyJM, YounesM. Expression of exportin 1 (XPO1/CRM1) in pancreatic adenocarcinoma. J Clin Oncol. 2017;35(4suppl):327. doi:10.1200/JCO.2017.35.4_suppl.327.
  • CornoC, StucchiS, De CesareM, et al. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochem Pharmacol. 2018;147:93–103. doi:10.1016/j.bcp.2017.11.009.29155058
  • NairJS, MusiE, SchwartzGK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and down-regulation of survivin. Clin Cancer Res. 2017;23(15):4301–4311. doi:10.1158/1078-0432.CCR-16-2632.28314790
  • Karyopharm Therapeutics. Karyopharm announces FDA approval of XPOVIO™ (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma [media release]. 2019.
  • Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma. Available from: https://investors.karyopharm.com/2021-01-29-Karyopharm-Receives-Positive-CHMP-Opinion-for-NEXPOVIO-R-selinexor-for-the-Treatment-of-Patients-with-Refractory-Multiple-Myeloma. Accessed 326, 2021.
  • LinQ, XieS, QiuX, ChenJ, XuRA. Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo. Infect Drug Resist. 2019;12:1021–1027. doi:10.2147/IDR.S19952631118708
  • LiSL, ZhuYL, ZhuCY, et al. Simultaneous determination of parecoxib and its metabolite valdecoxib concentrations in beagle plasma by UPLC-MS/MS and application for pharmacokinetics study. Drug Des Devel Ther. 2020;14:1117–1125. doi:10.2147/DDDT.S226349
  • ZhouW, LiSL, ZhaoT, et al. Effects of dexmedetomidine on the pharmacokinetics of dezocine, midazolam and its metabolite 1-hydroxymidazolam in beagles by UPLC-MS/MS. Drug Des Devel Ther. 2020;14:2595–2605. doi:10.2147/DDDT.S254055
  • US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD, USA: US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research; 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalyticalmethod-validation-guidance-industry. Accessed 810, 2018.
  • LiSL, ZhangY, ChengQS, et al. UPLC-MS/MS measurement of the effect of isavuconazole, itraconazole and fluconazole on the pharmacokinetics of selinexor in rats. Infect Drug Resist. 2020;13:3153–3161. doi:10.2147/IDR.S26983132982330

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.